• LAST PRICE
    4.2500
  • TODAY'S CHANGE (%)
    Trending Down-0.1700 (-3.8462%)
  • Bid / Lots
    4.2200/ 1
  • Ask / Lots
    4.8400/ 5
  • Open / Previous Close
    4.3400 / 4.4200
  • Day Range
    Low 4.2400
    High 4.4700
  • 52 Week Range
    Low 3.5275
    High 47.0000
  • Volume
    4,189
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 4.42
TimeVolumeSNPX
09:56 ET2204.34
10:15 ET11764.31
10:17 ET1004.47
11:58 ET4004.3474
12:07 ET3004.3
01:19 ET1974.24
01:33 ET2004.265
01:48 ET2414.3
03:14 ET1004.258
03:16 ET4044.26
03:34 ET1004.326
03:50 ET1404.25
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSNPX
Synaptogenix Inc
5.5M
-0.1x
---
United StatesEFTR
eFFECTOR Therapeutics Inc
5.5M
-0.1x
---
United StatesADIL
Adial Pharmaceuticals Inc
5.4M
-0.2x
---
United StatesKTTA
Pasithea Therapeutics Corp
5.4M
-0.3x
---
United StatesPRTG
Portage Biotech Inc
5.5M
0.0x
---
United StatesLIXT
Lixte Biotechnology Holdings Inc
5.6M
-1.0x
---
As of 2024-06-20

Company Information

Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.

Contact Information

Headquarters
1185 AVENUE OF THE AMERICAS, 3RD FLOORNEW YORK, NY, United States 10036
Phone
973-242-0005
Fax
302-655-5049

Executives

Independent Chairman of the Board
Joshua Silverman
President, Chief Scientific Officer, Director
Daniel Alkon
Chief Executive Officer, Director
Alan Tuchman
Independent Non-Executive Vice Chairman of the Board
William Singer
Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Robert Weinstein

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$5.5M
Revenue (TTM)
$0.00
Shares Outstanding
1.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.47
EPS
$-37.38
Book Value
$26.55
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.